Department of Pharmacy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510030, China.
College of Pharmacy, Jinan University, Guangzhou 510632, China.
Immunotherapy. 2021 Jun;13(8):661-668. doi: 10.2217/imt-2020-0237. Epub 2021 Apr 20.
To evaluate the cost-effectiveness of ribociclib plus fulvestrant versus fulvestrant in hormone receptor-positive/human EGF receptor 2-negative advanced breast cancer. A three-state Markov model was developed to evaluate the costs and effectiveness over 10 years. Direct costs and utility values were obtained from previously published studies. We calculated incremental cost-effectiveness ratio to evaluate the cost-effectiveness at a willingness-to-pay threshold of $150,000 per additional quality-adjusted life year. The incremental cost-effectiveness ratio was $1,073,526 per quality-adjusted life year of ribociclib plus fulvestrant versus fulvestrant. Ribociclib plus fulvestrant is not cost-effective versus fulvestrant in the treatment of advanced hormone receptor-positive/human EGF receptor 2-negative breast cancer. When ribociclib is at 10% of the full price, ribociclib plus fulvestrant could be cost-effective.
评估 CDK4/6 抑制剂（如瑞博西利）联合氟维司群对比氟维司群在激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌中的成本效果。采用三状态 Markov 模型，评估 10 年的成本和效果。直接成本和效用值来源于已发表的研究。我们计算了增量成本效果比，以评估在 15 万美元/QALY 的意愿支付阈值下的成本效果。瑞博西利联合氟维司群对比氟维司群每增加 1 个 QALY 的增量成本效果比为 1073526 美元。在治疗激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌方面，瑞博西利联合氟维司群对比氟维司群不具有成本效果。当瑞博西利的价格降低至原价的 10%时，瑞博西利联合氟维司群可能具有成本效果。
